GLEAVE, MARTIN,RENNIE, PAUL S.,MIYAKE, HIDEAKI,NELSON, COLLEEN
申请号：
CA2371814
公开号：
CA2371814C
申请日:
2000.02.25
申请国别(地区):
CA
年份:
2014
代理人:
摘要：
It has now been determined that antisense therapy which reduces the expressionof TRPM-2 provides therapeutic benefits in the treatment of cancer. Inparticular, such antisense therapy can be applied in treatment of prostatecancer and renal cell cancer. Addition of antisense TRPM-2 ODN to prostatictumor cells in vivo is effective for delaying the onset of androgenindependence. Thus, prostate cancer can be treated in an individual sufferingfrom prostate cancer by initiating androgen-withdrawal to induce apoptoticcell death of prostatic tumor cells in the individual, and administering tothe individual a composition effective to inhibit expression of TRPM-2 by thetumor cells, thereby delaying the progression of prostatic tumor cells to anandrogen-independent state in an individual. Combined use of antisense TRPM-2and taxanes synergistically enhances cytotoxic chemosensitivity of androgen-independent prostate cancer. In addition, it has also been found thatantisense TRPM-2 has beneficial effect for other cancer types. Specifically,antisense TRPM-2 ODN enhances chemosensitivity in human Renal cell cancer, anormally chemoresistant disease with no active chemotherapeutic agent havingan objective response rate higher than 10 %. Radiation sensitivity is alsoenhanced when cells expressing TRPM-2 are treated with antisense TRPM-2 ODN.Thus, the antisense TRPM-2 ODNs can be used to enhance hormone sensitivity,chemosensitivity and radiation sensitivity of a variety of cancer types inwhich expression of TRPM-2 has been observed.
